Mirshahi M, Soria J, Soria C, Perrot J Y, Boucheix C
Thromb Res. 1986 Dec 15;44(6):715-28. doi: 10.1016/0049-3848(86)90018-6.
We have developed a latex immunoassay using an anti D neo monoclonal antibody (F2C5) which recognizes an epitope present in fragment D but which is hidden in intact fibrinogen and in early fibrinogen degradation products. This technique was applied directly to plasma of both healthy donors and patients, and was shown to be very convenient for clinical investigation, especially in emergency cases for diagnosis of intravascular coagulation. The use of plasma samples instead of serum offers several advantages: it is not time consuming since blood clotting is not required; it avoids overestimation when fibrinogen cannot be totally clotted, and underestimation due to the binding of nonclottable fibrin degradation products to the clot during clotting in vitro. This monoclonal antibody, which reacts more with FbDP (expressed in fragment D) than with fragment D, does not allow fibrin and fibrinogen degradation products to be differentiated. However, this discrimination does not seem critical for its clinical use since the level of fragment D neo antigen remained within the normal range in 12 cases of spontaneous or venous occlusion-induced hyperfibrinolysis.
我们利用一种抗D新单克隆抗体（F2C5）开发了一种乳胶免疫测定法，该抗体识别存在于片段D中的一个表位，但该表位在完整的纤维蛋白原和早期纤维蛋白原降解产物中是隐藏的。这项技术直接应用于健康供体和患者的血浆，并且已证明对临床研究非常方便，特别是在诊断血管内凝血的紧急情况下。使用血浆样本而非血清有几个优点：不需要血液凝固，因此不耗时；当纤维蛋白原不能完全凝固时可避免高估，并且可避免由于体外凝血过程中不可凝固的纤维蛋白降解产物与凝块结合导致的低估。这种单克隆抗体与FbDP（在片段D中表达）的反应比与片段D的反应更强，无法区分纤维蛋白和纤维蛋白原降解产物。然而，这种区分对于其临床应用似乎并不关键，因为在12例自发性或静脉闭塞性高纤维蛋白溶解病例中，片段D新抗原水平仍在正常范围内。
